1. Biochemistry and Chemical Biology
  2. Microbiology and Infectious Disease
Download icon

Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration

  1. Qi Yang
  2. Thomas A Hughes
  3. Anju Kelkar
  4. Xinheng Yu
  5. Kai Cheng
  6. Sheldon Park
  7. Wei-Chiao Huang
  8. Jonathan F Lovell
  9. Sriram Neelamegham  Is a corresponding author
  1. State University of New York at Buffalo, United States
Research Article
  • Cited 33
  • Views 5,093
  • Annotations
Cite this article as: eLife 2020;9:e61552 doi: 10.7554/eLife.61552

Abstract

The Spike protein of SARS-CoV-2, its receptor binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated. The impact of this post-translational modification on viral entry is yet unestablished. We expressed different glycoforms of the Spike-protein and ACE2 in CRISPR-Cas9 glycoengineered cells, and developed corresponding SARS-CoV-2 pseudovirus. We observed that N- and O-glycans had only minor contribution to Spike-ACE2 binding. However, these carbohydrates played a major role in regulating viral entry. Blocking N-glycan biosynthesis at the oligomannose stage using both genetic approaches and the small molecule kifunensine dramatically reduced viral entry into ACE2 expressing HEK293T cells. Blocking O-glycan elaboration also partially blocked viral entry. Mechanistic studies suggest multiple roles for glycans during viral entry. Among them, inhibition of N-glycan biosynthesis enhanced Spike-protein proteolysis. This could reduce RBD presentation on virus, lowering binding to host ACE2 and decreasing viral entry. Overall, chemical inhibitors of glycosylation may be evaluated for COVID-19.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. All plasmids generated by the authors will be deposited at Addgene.

Article and author information

Author details

  1. Qi Yang

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Qi Yang, Co-author of a provisional patent application.(63/079,667).
  2. Thomas A Hughes

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Thomas A Hughes, Co-author of a provisional patent application.(63/079,667).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7887-6876
  3. Anju Kelkar

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    Anju Kelkar, Co-author of a provisional patent application.(63/079,667).
  4. Xinheng Yu

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  5. Kai Cheng

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  6. Sheldon Park

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  7. Wei-Chiao Huang

    Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
  8. Jonathan F Lovell

    Department of Biomedical Engineering, State University of New York at Buffalo, Buffalo, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9052-884X
  9. Sriram Neelamegham

    Department of Chemical and Biological Engineering, State University of New York at Buffalo, Buffalo, United States
    For correspondence
    neel@buffalo.edu
    Competing interests
    Sriram Neelamegham, Co-author of a provisional patent application.(63/079,667).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1371-8500

Funding

National Institutes of Health (HL103411)

  • Sriram Neelamegham

National Institutes of Health (GM133195)

  • Sriram Neelamegham

National Institutes of Health (GM126537)

  • Sriram Neelamegham

National Institutes of Health (GM139160)

  • Sheldon Park
  • Sriram Neelamegham

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Malcolm J McConville, The University of Melbourne, Australia

Publication history

  1. Received: July 29, 2020
  2. Accepted: October 24, 2020
  3. Accepted Manuscript published: October 26, 2020 (version 1)
  4. Version of Record published: November 24, 2020 (version 2)

Copyright

© 2020, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,093
    Page views
  • 740
    Downloads
  • 33
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

  1. Further reading

Further reading

    1. Biochemistry and Chemical Biology
    Xavier Portillo et al.
    Research Article Updated

    An RNA polymerase ribozyme that has been the subject of extensive directed evolution efforts has attained the ability to synthesize complex functional RNAs, including a full-length copy of its own evolutionary ancestor. During the course of evolution, the catalytic core of the ribozyme has undergone a major structural rearrangement, resulting in a novel tertiary structural element that lies in close proximity to the active site. Through a combination of site-directed mutagenesis, structural probing, and deep sequencing analysis, the trajectory of evolution was seen to involve the progressive stabilization of the new structure, which provides the basis for improved catalytic activity of the ribozyme. Multiple paths to the new structure were explored by the evolving population, converging upon a common solution. Tertiary structural remodeling of RNA is known to occur in nature, as evidenced by the phylogenetic analysis of extant organisms, but this type of structural innovation had not previously been observed in an experimental setting. Despite prior speculation that the catalytic core of the ribozyme had become trapped in a narrow local fitness optimum, the evolving population has broken through to a new fitness locale, raising the possibility that further improvement of polymerase activity may be achievable.

    1. Biochemistry and Chemical Biology
    Gajanan S Patil et al.
    Research Article Updated

    Fatty acyl-AMP ligases (FAALs) channelize fatty acids towards biosynthesis of virulent lipids in mycobacteria and other pharmaceutically or ecologically important polyketides and lipopeptides in other microbes. They do so by bypassing the ubiquitous coenzyme A-dependent activation and rely on the acyl carrier protein-tethered 4′-phosphopantetheine (holo-ACP). The molecular basis of how FAALs strictly reject chemically identical and abundant acceptors like coenzyme A (CoA) and accept holo-ACP unlike other members of the ANL superfamily remains elusive. We show that FAALs have plugged the promiscuous canonical CoA-binding pockets and utilize highly selective alternative binding sites. These alternative pockets can distinguish adenosine 3′,5′-bisphosphate-containing CoA from holo-ACP and thus FAALs can distinguish between CoA and holo-ACP. These exclusive features helped identify the omnipresence of FAAL-like proteins and their emergence in plants, fungi, and animals with unconventional domain organizations. The universal distribution of FAALs suggests that they are parallelly evolved with FACLs for ensuring a CoA-independent activation and redirection of fatty acids towards lipidic metabolites.